Despite widespread publicity, the 2002 landmark study on the potential dangers of hormone therapy for postmenopausal women is completely unknown to most women. New research from the Stanford University School of Medicine discovered that only 29 percent of the women surveyed knew anything about the study two years later. Additionally, only 40 percent of the… Read More »
Research has shown that cognitive behavioral therapy is as effective as maintenance antidepressant medication for preventing depression recurrence or relapse in individuals who have had successful depression treatment. According to the study authors, recurrence and relapse following recovery from major depression are typical outcomes that come with tremendous familial, personal and societal costs. The existing… Read More »
FDA Approves Viltepso (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy Print this page PARAMUS, N.J., Aug. 12, 2020 /PRNewswire/ — NS Pharma, Inc. announced today that the U.S. Food & Drug Administration (FDA) has approved Viltepso (viltolarsen) injection for patients with Duchenne muscular dystrophy (DMD) who… Read More »